| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9008466a40998f8be8e54cd3aceb10a2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65B7-285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65B31-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65B3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08 |
| filingDate |
2012-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a64b229bcadb27054cf0f5585ac0b84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa033c33eacaddca9226c83077df7b38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62dce707351c9f6c72c76d52e537b711 |
| publicationDate |
2012-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CL-2012001705-A1 |
| titleOfInvention |
Pharmaceutical composition comprising a) glycopyrronium bromide, b) formoterol or formoterol fumarate and c) beclomethasone dipropionate, dissolved in hfa134a and ethanol (between 10-15% w / w), 1m hcl between 0.15-0.28µg / µl; jar; pharmaceutical combination; method of filling the jar; and its use in asthma and / or copd |
| abstract |
The application 201201705 describes a pharmaceutical composition comprising (a) glycopyrronium bromide in a dose range of 0.5-100 µg per actuation; and (b) formoterol or formoterol fumarate in a dose range of 1-25 µg per actuation; dissolved in an HFA propellant (HFA 134a, HFA 227 or mixtures thereof) and a cosolvent (ethanol, in the range between 5-25% w / w), where said composition contains an amount of 1M HCl is in the range of 0.1-0.3 µg / µL. |
| priorityDate |
2009-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |